Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 12;20(1):338.
doi: 10.1186/s12957-022-02790-0.

Development and validation of an extended Cox prognostic model for patients with ER/PR+ and HER2- breast cancer: a retrospective cohort study

Yiqun Xie #  1 , Xizhou Li #  2 , Ying Wu #  3 , Wenting Cui  3 , Yang Liu  4
Affiliations

Development and validation of an extended Cox prognostic model for patients with ER/PR+ and HER2- breast cancer: a retrospective cohort study

Yiqun Xie et al. World J Surg Oncol. .

Abstract

Background: The purpose of this study was to explore a new estrogen receptor (ER) and/or progesterone receptor (PR)+ and human epidermal growth factor receptor 2 (HER2)- breast cancer prognostic model, called the extended Cox prognostic model, for determining the cutoff values for multiple continuous prognostic factors and their interaction via the new model concept and variable selection method.

Methods: A total of 335 patients with ER/PR+ and HER2- breast cancer were enrolled for the final analysis. The primary endpoint was breast cancer-specific mortality (BCSM). Prognostic factors (histological grade, histological type, stage, T, N, lymphovascular invasion (LVI), P53, Ki67, ER, PR, and age) were included in this study. The four continuous variables (Ki67, ER, PR, and age) were partitioned into a series of binary variables that were fitted in the multivariate Cox analysis. A smoothly clipped absolute deviation (SCAD) variable selection method was used. Model performance was expressed in discrimination and calibration.

Results: We developed an extended Cox model with a time threshold of 164-week (more than 3 years) postoperation and developed a user-friendly nomogram based on our extended Cox model to facilitate clinical application. We found that the cutoff values for PR, Ki67, and age were 20%, 60%, and 41-55 years, respectively. There was an interaction between age and PR for patients aged ≥ 41 years and PR ≥ 20% at 164-week postoperation: the older the patients with ER/PR+, HER2-, and PR ≥ 20% were, the lower the survival and more likely to recur and metastasize exceeding 164 weeks (more than 3 years) after surgery.

Conclusions: Our study offers guidance on the prognosis of patients with ER/PR+ and HER2- breast cancer in China. The new concept can inform modeling and the determination of cutoff values of prognostic factors in the future.

Keywords: Breast cancer; Clinicopathological prognostic factor; Estrogen receptor; Human epidermal growth factor receptor 2; Progesterone receptor; Prognostic model.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Patient’s selection
Fig. 2
Fig. 2
Kaplan-Meier survival probability curves
Fig. 3
Fig. 3
Nomogram of 1-year, 3-year, and 5-year survival probability
Fig. 4
Fig. 4
ROC curves for our extended Cox prognostic model at 1-year, 3-year, and 5-year postoperation
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Liao J, Li M, Gan J, Xiao J, Xiang G, Ding X, et al. Systematic review and meta-analysis of the efficacy of general anesthesia combined with a thoracic nerve block in modified breast cancer surgery. Gland Surg. 2021;10:3106–3115. doi: 10.21037/gs-21-719. - DOI - PMC - PubMed
    1. Li N, Cai H, Song K, Guo Y, Liang Q, Zhang J, et al. A five-gene-pair-based prognostic signature for predicting the relapse risk of early stage ER+ breast cancer. Front Genet. 2020;11:566928. doi: 10.3389/fgene.2020.566928. - DOI - PMC - PubMed
    1. Goldstein DA, Mayer C, Shochat T, Reinhorn D, Moore A, Sarfaty M, et al. The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real-world early-stage breast cancer. Cancer Med. 2020;9:4603–4612. doi: 10.1002/cam4.3088. - DOI - PMC - PubMed
    1. Burstein HJ, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;30:1541–1557. doi: 10.1093/annonc/mdz235. - DOI - PubMed
    1. Orucevic A, Bell JL, McNabb AP, Heidel RE. Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data. Breast Cancer Res Treat. 2017;163:51–61. doi: 10.1007/s10549-017-4170-3. - DOI - PMC - PubMed